Rivaroxaban for children over 2 with giant coronary artery aneurysms after Kawasaki disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial uses a Chinese-specific, model-informed 15 mg-equivalent, age- and weight-adjusted dosing regimen for rivaroxaban developed from pharmacokinetic simulations and prior pilot data. It is an open-label, randomized, exploratory trial with a 2:1 randomization comparing rivaroxaban plus aspirin or clopidogrel to warfarin plus aspirin or clopidogrel. Study staff will collect baseline features, bleeding events, adverse events, adherence, and thrombotic outcomes to characterize feasibility, safety, and effectiveness. Given the low incidence of giant coronary aneurysms, the study prioritizes safety and feasibility signals over definitive efficacy conclusions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;
2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 3 months;
3. Participant should be able to tolerate oral feeding, nasogastric or gastric feeding;
4. Children aged ≥ 2 years

Exclusion Criteria:

1. Active bleeding or bleeding risk contraindicating anticoagulant therapy
2. With history of venous thromboembolism or risk factors related with venous thromboembolism, like congenital heart disease, carcinoma, central venous catheter or long-term immobilization.
3. Thrombus within giant coronary aneurysm was confirmed by previous imaging examinations, including two-dimensional echocardiography, computed tomography angiography in coronary artery or coronary angiography
4. An eGFR \<30mL/min/1.73 m2 (For children younger than 1 year, serum creatinine results above 97.5th percentile)
5. Platelet count \< 100 x 109/L
6. Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase \> 5x ULN or total bilirubin \> 2x ULN with direct bilirubin \> 20% of the total
7. Sustained uncontrolled hypertension defined as systolic and/or diastolic blood pressure \>95 th age percentile
8. Concomitant use of strong inhibitors of both CYP3A4 and P-glycoprotein, including but not limited to all human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed)
9. Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
10. Hypersensitivity or any other contraindications listed in the local labeling for the comparator treatment or experimental treatment
11. Inability to cooperate with the study procedures and follow-up visits
12. Refuse to provide informed consent eGFR, estimated glomerular filtration rate; ULN, upper level of normal; TB, total bilirubin; CYP3A4, cytochrome P450 isoenzyme 3A4

Where it's running

• Children's Hospital of Fudan University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Fang Liu, MD
• Email: liufang@fudan.edu.cn
• Phone: 18017590880

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing Rivaroxaban in Chinese Children with Kawasaki Disease

  This study is testing how well the blood thinner rivaroxaban works in children with Kawasaki disease who have serious heart problems.

  Recruiting Children's Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06993636

• Optimizing Rivaroxaban Dosing for Children with Giant Coronary Aneurysms After Kawasaki Disease

  This study is testing a new way to dose a blood thinner called rivaroxaban for Chinese children with giant coronary aneurysms after Kawasaki disease to see if it helps prevent heart problems.

  Recruiting Phase 4 Children's Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06978439

• Atorvastatin in Chinese children with Kawasaki disease and coronary artery abnormalities

  This phase 3 study tests whether atorvastatin is safe and helpful for children with Kawasaki disease who have coronary artery abnormalities.

  Recruiting Phase 3 Children's Hospital of Fudan University · Shanghai · NCT07530640

• Kawasaki MATCH decision support for suspected Kawasaki disease

  This study will test a machine-learning tool called Kawasaki MATCH to help providers decide if febrile children might have Kawasaki disease.

  Recruiting University of California, San Diego · San Diego, California · NCT07291245

• Cardiovascular health in children and young adults with chronic conditions

  This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.

  Recruiting Semmelweis University · Budapest and 2 other locations · NCT07086989

• Observing Kawasaki disease in European and North Indian children

  This study looks at children with Kawasaki disease to see if certain scoring systems can help identify those who don't respond to standard treatment, focusing on kids from Europe and North India.

  Recruiting at 17 sites Meyer Children's Hospital IRCCS · Rio de Janeiro and 26 other locations · NCT06305611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.